Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.